Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
US8216575B2 · kind B2 · utility
32Cited by
3References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 11, 2009 |
| Grant date | Jul 10, 2012 |
| Priority date | — |
| Expiry date | Sep 30, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are novel soluble chimeric fusion proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including domain 4 of KDR. The claimed chimeric fusion proteins antagonize the endothelial cell proliferative and angiogenic activity of VEGF and are useful in the treatment of neovascularization-related disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.